Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samplesReport as inadecuate




Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples - Download this document for free, or read online. Document in PDF available to download.

Liquid chromatography-tandem mass spectrometry was used to analyze plasma proteins of volunteers control and patients with glioblastoma multiform GBM. A database search was pre-set with a variable post-translational modification PTM: phosphorylation, acetylation or ubiquitination. There were no significant differences between the control and the GBM groups regarding the number of protein identifications, sequence coverage or number of PTMs. However, in GBM plasma, we unambiguously observed a decreased fraction in post-translationally modified peptides identified with high quality. The disease-specific PTM patterns were extracted and mapped to the set of FDA-approved plasma protein markers. Decreases of 46% and 24% in the number of acetylated and ubiquitinated peptides, respectively, were observed in the GBM samples. Significance of capturing disease-associated patterns of protein modifications was envisaged.



Author: Natalia A. Petushkova , Victor G. Zgoda, Mikhail A. Pyatnitskiy, Olesya V. Larina, Nadezhda B. Teryaeva, Alexander A. Potapov, An

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents